# A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

> **NCT04449874** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 498 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Advanced Solid Tumors

## Interventions

- **DRUG:** GDC-6036
- **DRUG:** Atezolizumab
- **DRUG:** Cetuximab
- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib
- **DRUG:** GDC-1971
- **DRUG:** Inavolisib

## Key facts

- **NCT ID:** NCT04449874
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 498 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04449874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04449874, "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04449874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*